Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
Alcon (SIX/NYSE: ALC) has announced that CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. The presentation will be available via live webcast on the company's investor relations website.
Alcon, the global leader in eye care with a 75+ year heritage, serves over 260 million people annually across 140+ countries through their Surgical and Vision Care products. The company focuses on treating conditions including cataracts, glaucoma, retinal diseases, and refractive errors. With more than 25,000 associates, Alcon works to enhance quality of life through innovative products, partnerships with Eye Care Professionals, and programs advancing access to quality eye care.
Alcon (SIX/NYSE: ALC) ha annunciato che il CEO David Endicott presenterà alla Conferenza Sanitaria J.P. Morgan 2025 martedì 14 gennaio 2025 alle 16:30 PST. La presentazione sarà disponibile in diretta streaming sul sito web delle relazioni con gli investitori dell'azienda.
Alcon, leader globale nel settore della cura degli occhi con oltre 75 anni di esperienza, serve annualmente più di 260 milioni di persone in oltre 140 paesi attraverso i suoi prodotti per la chirurgia e la cura della vista. L'azienda si concentra sul trattamento di condizioni come cataratte, glaucoma, malattie retiniche e errori refrattivi. Con più di 25.000 associati, Alcon lavora per migliorare la qualità della vita attraverso prodotti innovativi, partnership con professionisti della cura degli occhi e programmi che promuovono l'accesso a cure oculari di qualità.
Alcon (SIX/NYSE: ALC) ha anunciado que el CEO David Endicott presentará en la Conferencia de Salud J.P. Morgan 2025 el martes 14 de enero de 2025 a las 4:30 p.m. PST. La presentación estará disponible a través de una transmisión en vivo en el sitio web de relaciones con los inversores de la empresa.
Alcon, líder global en el cuidado de los ojos con más de 75 años de experiencia, atiende anualmente a más de 260 millones de personas en más de 140 países a través de sus productos de cirugía y cuidado de la visión. La empresa se centra en el tratamiento de condiciones como cataratas, glaucoma, enfermedades de la retina y errores refractivos. Con más de 25.000 asociados, Alcon trabaja para mejorar la calidad de vida a través de productos innovadores, asociaciones con profesionales del cuidado de los ojos y programas que avanzan el acceso a una atención ocular de calidad.
Alcon (SIX/NYSE: ALC)는 CEO David Endicott가 2025 J.P. 모건 헬스케어 컨퍼런스에서 2025년 1월 14일 화요일 오후 4:30 PST에 발표할 것이라고 발표했습니다. 이 발표는 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 제공될 예정입니다.
Alcon은 75년 이상의 전통을 가진 글로벌 안구 관리 기업으로, 매년 1억 2천 6백만 명 이상의 사람들에게 140개국 이상에서 수술 및 시력 관리 제품을 통해 서비스를 제공합니다. 이 회사는 백내장, 녹내장, 망막 질환 및 굴절 오류와 같은 질환 치료에 중점을 두고 있습니다. 25,000명 이상의 직원과 함께 Alcon은 혁신적인 제품, 안과 전문의와의 파트너십 및 양질의 안과 치료 접근을 촉진하는 프로그램을 통해 삶의 질을 향상시키기 위해 노력하고 있습니다.
Alcon (SIX/NYSE: ALC) a annoncé que le PDG David Endicott présentera à la Conférence de Santé J.P. Morgan 2025 le mardi 14 janvier 2025 à 16h30 PST. La présentation sera disponible en direct sur le site internet des relations investisseurs de l'entreprise.
Alcon, le leader mondial des soins oculaires avec plus de 75 ans d'histoire, sert plus de 260 millions de personnes chaque année dans plus de 140 pays grâce à ses produits de chirurgie et de soins de la vue. L'entreprise se concentre sur le traitement de conditions telles que les cataractes, le glaucome, les maladies rétiniennes et les erreurs de réfraction. Avec plus de 25 000 collaborateurs, Alcon s'efforce d'améliorer la qualité de vie grâce à des produits innovants, des partenariats avec des professionnels des soins oculaires et des programmes favorisant l'accès à des soins oculaires de qualité.
Alcon (SIX/NYSE: ALC) hat angekündigt, dass CEO David Endicott am 2025 J.P. Morgan Healthcare Conference am Dienstag, den 14. Januar 2025, um 16:30 Uhr PST präsentieren wird. Die Präsentation wird über einen Live-Stream auf der Investor-Relations-Website des Unternehmens verfügbar sein.
Alcon, der globale Marktführer in der Augenpflege mit über 75 Jahren Erfahrung, betreut jährlich mehr als 260 Millionen Menschen in über 140 Ländern mit seinen chirurgischen und Sehpflegeprodukten. Das Unternehmen konzentriert sich auf die Behandlung von Erkrankungen wie Katarakten, Glaukom, Netzhauterkrankungen und Refraktionsfehlern. Mit mehr als 25.000 Mitarbeitern arbeitet Alcon daran, die Lebensqualität durch innovative Produkte, Partnerschaften mit Augenpflege-Profis und Programme zur Verbesserung des Zugangs zu hochwertiger Augenpflege zu fördern.
- None.
- None.
Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST.
A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us on
View source version on businesswire.com: https://www.businesswire.com/news/home/20241231746694/en/
Investor Relations
Daniel Cravens
Allen Trang
+ 41 589 112 110 (
+ 1 817 615 2789 (
investor.relations@alcon.com
Media Relations
Steven Smith
+ 41 589 112 111 (
+ 1 817 551 8057 (
globalmedia.relations@alcon.com
Source: Alcon Inc. Swiss
FAQ
When is Alcon (ALC) presenting at the 2025 J.P. Morgan Healthcare Conference?
How many countries does Alcon (ALC) operate in as of 2025?
How many patients does Alcon (ALC) serve annually?
What medical conditions does Alcon (ALC) address through its products?
How many employees does Alcon (ALC) have as of 2025?
Where can investors watch Alcon's (ALC) J.P. Morgan Healthcare Conference presentation?
